iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

Cancer Cells
(Shutterstock)

The TIGIT class claimed its latest casualty as iTeos Therapeutics’ belrestotug failed to show sufficient benefit in trials of patients with non-small cell lung cancer (NSCLC) and head and neck cancer, leading them to call off the drug’s development program. It is a major letdown even for a class that has seen several failures as belrestotug had been considered a leader among TIGIT inhibitors. The trial results led iTeos and partner GSK plc to terminate their collaboration and forced iTeos to pursue strategic alternatives.

Key Takeaways
  • iTeos said it is pursuing strategic alternatives after Phase II studies of belrestotug failed to meet efficacy expectations.

The Belgian-American biotech disclosed on 13 May the results of the Phase II GALAXIES Lung-02 platform study testing the combination...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immuno-oncology

More from Scrip